Active surveillance of prostate cancer in African American men

Urology

Volumn 84, Issue 6, 2014, Pages 1255-1262

  Silberstein, Jonathan L ^a   Feibus, Allison H ^a   Maddox, Michael M ^a   Abdel Mageed, Asim B ^a   Moparty, Krishnarao ^a   Thomas, Raju ^a   Sartor, Oliver ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SURVEILLANCE; AFRICAN AMERICAN; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER SCREENING; FOLLOW UP; GLEASON SCORE; HUMAN; LOW RISK PATIENT; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW; WATCHFUL WAITING; AGE; BLOOD; CANCER STAGING; ETHNOLOGY; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; TUMOR INVASION; VERY ELDERLY;

PROSTATE SPECIFIC ANTIGEN;

AFRICAN AMERICANS; AGE FACTORS; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; WATCHFUL WAITING;

EID: 84922277700     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2014.06.064     Document Type: Review

References (50)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer Statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. P. Albertsen, J. Hanley, and J. Fine 20-Year outcomes following conservative management of clinically localized prostate cancer JAMA 293 2005 2095 2101
3. S.E. Eggener, P.T. Scardino, and P.C. Walsh et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy J Urol 185 2011 869 875
4. H.B. Carter, A.W. Partin, and P.C. Walsh et al. Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol 30 2012 4294 4296
5. M.R. Cooperberg, J.M. Boering, and P.R. Carroll Time trends and local variation in primary treatment of localized prostate cancer J Clin Oncol 28 2010 1117 1123
6. G.B. Taksler, N.L. Keating, and D.M. Cutler Explaining racial differences in prostate cancer mortality Cancer 118 2012 4280 4289
7. I.J. Powell Epidemiology and pathophysiology of prostate cancer in African-American men J Urol 177 2007 444 449
8. S. Evans, C. Metcalfe, and F. Ibrahim et al. Investigating Black-White differences in prostate cancer prognosis: a systematic review and meta-analysis Int J Cancer 123 2008 430 435
9. Y.-S. Ha, A. Salmasi, and M. Karellas et al. Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance Urology 81 2013 831 835
10. D. Sundi, A.E. Ross, and E.B. Humphreys et al. African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol 31 2013 2991 2997
11. A. Vora, T. Large, and J. Aronica et al. Predictors of Gleason score upgrading in a large African-American population Int Urol Nephrol 45 2013 1257 1262
12. J.J. Tosoian, B.J. Trock, and P. Landis et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience J Clin Oncol 29 2011 2185 2190
13. M.S. Soloway, C.T. Soloway, and A. Eldefrawy et al. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment Eur Urol 58 2010 831 835
14. V. Iremashvili, M.S. Soloway, and D.L. Rosenberg et al. Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance J Urol 187 2012 1594 1599
15. M.R. Cooperberg, J.E. Cowan, and J.F. Hilton et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer J Clin Oncol 29 2011 228 234
16. R.C. van den Bergh, S. Roemeling, and M.J. Roobol et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly Eur Urol 55 2009 1 8
17. N.J. van As, A.R. Norman, and K. Thomas et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance Eur Urol 54 2008 1297 1305
18. A. Adamy, D.S. Yee, and K. Matsushita et al. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer J Urol 185 2011 477 482
19. L. Klotz, L. Zhang, and A. Lam et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126 131
20. M.R. Abern, M.R. Bassett, and M. Tsivian et al. Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the Duke Prostate Center Prostate Cancer Prostatic Dis 16 2013 85 90
21. M.A. Bjurlin, H.B. Carter, and P. Schellhammer et al. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing J Urol 189 2013 2039 2046
22. B.J. Linder, I. Frank, and E.C. Umbreit et al. Standard and saturation transrectal prostate biopsy techniques are equally accurate among prostate cancer active surveillance candidates Int J Urol 20 2013 860 864
23. J.I. Epstein, Z. Feng, and B.J. Trock et al. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades Eur Urol 61 2012 1019 1024
24. R.K. Berglund, T.A. Masterson, and K.C. Vora et al. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance J Urol 180 2008 1964 1967 discussion 1967-8
25. J.J. Tosoian, E. JohnBull, and B.J. Trock et al. Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance J Urol 190 2013 1218 1222
26. D. Sundi, O.N. Kryvenko, and H.B. Carter et al. Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men J Urol 191 2013 1 8
27. R.F. Sanchez-Ortiz, P. Troncoso, and R.J. Babaian et al. African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men Cancer 107 2006 75 82
28. K. Yamoah, N. Stone, and R. Stock Impact of race on biochemical disease recurrence after prostate brachytherapy Cancer 117 2011 5589 5600
29. M. Truong, J.A. Slezak, and C.P. Lin et al. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer Cancer 119 2013 1 11
30. A.S. Moussa, M.W. Kattan, and R. Berglund et al. A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling BJU Int 105 2010 352 358
31. S.J. Freedland, C.J. Kane, and C.L. Amling et al. Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications Urology 69 2007 495 499
32. C.J. Kane, R. Im, and C.L. Amling et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database Urology 76 2010 695 700
33. B.D. Odom, M.C. Mir, and S. Hughes et al. Active surveillance for low-risk prostate cancer in African American men: a multi-institutional experience Urology 83 2014 364 368
34. J. Cullen, S.A. Brassell, and Y. Chen et al. Racial/ethnic patterns in prostate cancer outcomes in an active surveillance cohort Prostate Cancer 2011 2011 234519
35. M. Koscuiszka, D. Hatcher, and P.J. Christos et al. Impact of race on survival in patients with clinically nonmetastatic prostate cancer who deferred primary treatment Cancer 118 2012 3145 3152
36. T.J. Wilt, M.K. Brawer, and K.M. Jones et al. Radical prostatectomy versus observation for localized prostate cancer N Engl J Med 367 2012 203 213
37. M.M. Rawaf, and N.R. Kressin Exploring racial and sociodemographic trends in physician behavior, physician trust and their association with blood pressure control J Natl Med Assoc 99 2007 1248 1254
38. M.A. Gorin, C.T. Soloway, and A. Eldefrawy et al. Factors that influence patient enrollment in active surveillance for low-risk prostate cancer Urology 77 2011 588 591
39. W. Underwood, S. De Monner, and P. Ubel et al. Racial/ethnic disparities in the treatment of localized/regional prostate cancer J Urol 171 2004 1504 1507
40. J. Xu, A.V. Neale, and R.K. Dailey et al. Patient perspective on watchful waiting/active surveillance for localized prostate cancer J Am Board Fam Med 25 2012 763 770
41. D. Hessels, and J.A. Schalken Recurrent gene fusions in prostate cancer: their clinical implications and uses Curr Urol Rep 14 2013 214 222
42. P. Rosen, D. Pfister, and D. Young et al. Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer Urology 80 2012 749 753
43. D.W. Lin, L.F. Newcomb, and E.C. Brown et al. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from baseline analysis in the Canary Prostate Active Surveillance Study Clin Cancer Res 19 2013 2442 2450
44. R. Ross, L. Bernstein, and H. Judd et al. Serum testosterone levels in healthy young black and white men J Natl Cancer Inst 76 1986 45 48
45. H.J. Litman, S. Bhasin, and C.L. Link et al. Serum androgen levels in black, Hispanic, and white men J Clin Endocrinol Metab 91 2006 4326 4334
46. N.M. Makridakis, R.K. Ross, and M.C. Pike et al. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA Lancet 354 1999 975 978
47. E. Taioli, V. Sears, and A. Watson et al. Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent Prostate 73 2013 668 676
48. K.E. Gaston, D. Kim, and S. Singh et al. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer J Urol 170 2003 990 993
49. E.O. Olapade-Olaopa, C.A. Muronda, and E.H. MacKay et al. Androgen receptor protein expression in prostatic tissues in Black and Caucasian men Prostate 59 2004 460 468
50. O. Sartor, Q. Zheng, and J. Eastham Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer Urology 4295 1999 378 380